Rock Creek Pharmaceuticals Inc. (fka RCPIQ)

[knuts4oe]

Here are a couple of older papers which highlight Roskamp’s hypothesis that three factors combine to cause Alzheimer’s Disease, and that both nilvadipine and anatabine can reduce, and maybe block all three factors.

The first is the discovery, with nilvadipine, that all three factors are downstream from the Syk enzyme (spleen tyrosine kinase). Theoretically, targeting Syk should impact all three factors implicated in AD.

http://health.heraldtribune.com/2014/10/28/sarasota-scientists-excited-potential-alzheimers-breakthrough/

The second is a peer-reviewed and published study which focuses on anatabine’s potential to impact the three factors believed to be responsible for causing AD, and is clearly explained in the SUMMARY on page 1.




http://health.heraldtribune.com/2014/10/28/sarasota-scientists-excited-potential-alzheimers-breakthrough/